Biopol Chemicals Limited is engaged in the manufacturing of speciality polymer and chemical products primarily used in pharmaceutical, packaging, agrochemical, FMCG and industrial applications. The company earns revenue through the sale of customised polymer compounds and speciality chemical formulations, supplied on a B2B basis. Its products enhance durability, stability and performance of end-use products, making them critical inputs across multiple industries.


The Company is led by Promoter, i.e.,MR. SANTANU SARKAR AND MR. VEDANT SARKAR

The Revenues from operations for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 4,896.94 Lakh, ₹ 4,915.13 Lakh, ₹ 1,743.28 Lakh, and ₹ - Lakh, The EBITDA for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 899.27 Lakh, ₹ 653.39 Lakh, ₹ 442.71 Lakh, and ₹ - Lakh, The Profit after Tax for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 600.48 Lakh, ₹ 433.01 Lakh, ₹ 128.08 Lakh, and ₹ - Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue   EPS of  ₹ 5.47 and post-issue EPS of ₹  4.01 for FY25. The pre-issue P/E ratio is 19.74x,while the post-issue P/E ratio is 26.95x against the Industry P/E ratio is 10.14x The company's ROE for FY25 is 38.10% and RoNW is 32.00% The Annualised EPS is ₹ 7.41x and P/E is ₹ 14.58x,    These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of Biopol Chemicals showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Biopol Chemicals Limited. IPO for Listing gain or Long Term Purposes.